E. Paris

Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial.

J. Pignon, T. Conroy, E. Deutsch, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.

J. Pignon, L. Seymour, F. Shepherd, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Mesothelioma at era of helical tomotherapy: results of two institutions in combining chemotherapy, surgery and radiotherapy.

P. Giraud, M. Yassa, M. Mahé, 2011, Lung cancer.

Hepatic arterial infusion (HAI) of oxaliplatin plus intravenous (iv) fluorouracil (FU), leucovorin (LV), and cetuximab for first-line treatment of unresectable colorectal liver metastases (CRLM) (CHOICE): A multicenter phase II study.

J. Pignon, M. Ducreux, T. Baère, 2010 .

Helical tomotherapy for resected malignant pleural mesothelioma: dosimetric evaluation and toxicity.

P. Giraud, F. Le Pimpec Barthès, M. Mahé, 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Cetuximab plus radiochemotherapy in locally advanced anal cancer: Interim results of the French multicenter phase II trial ACCORD16.

J. Pignon, Y. Bécouarn, J. Bérille, 2011, Journal of Clinical Oncology.

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.

J. Pignon, L. Seymour, F. Shepherd, 2012 .